Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On February 27, 2023, Metacrine, Inc. (the "Company") was notified that The
Nasdaq Stock Market LLC ("Nasdaq") will delist the Company's common stock, par
value $0.0001 per share (the "Common Stock"), by filing a Form 25 with the
Securities and Exchange Commission (the "SEC") in accordance with Rule 12d2-2
promulgated under the Securities Exchange Act of 1934, as amended. On March 3,
2023, Nasdaq filed the Form 25 with the SEC. The delisting will become effective
on March 13, 2023, ten days after the filing of the Form 25.
As previously disclosed, the Common Stock was suspended from trading on The
Nasdaq Capital Market at the opening of business on February 9, 2023 as a result
of the Company's failure to regain compliance with the minimum bid price
requirement set forth in Nasdaq Listing Rule 5450(a)(1), and has since been
quoted on the OTC marketplace under the symbol "MTCR." Quotes and related
Company information are available at www.otcmarkets.com.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
METACRINE, INC. 
